IL-27 gene therapy induces Stat3-mediated expansion of CD11b+ Gr1+ myeloid cells and promotes accumulation of M1 macrophages in the tumor microenvironment

J Zhu, J Yu, A Hu, JQ Liu, X Pan, G Xin… - The Journal of …, 2023 - journals.aai.org
IL-27 is a pleiotropic cytokine that exhibits stimulatory/regulatory functions on multiple
lineages of immune cells and has a potential to be used as a therapeutic for cancer. We …

IL-27 Gene Therapy Induces Stat3-Mediated Expansion of CD11b+ Gr1+ Myeloid Cells and Promotes Accumulation of M1 Macrophages in the Tumor …

J Zhu, J Yu, A Hu, JQ Liu, X Pan, G Xin… - … (Baltimore, Md.: 1950 …, 2023 - europepmc.org
IL-27 is a pleiotropic cytokine that exhibits stimulatory/regulatory functions on multiple
lineages of immune cells and has a potential to be used as a therapeutic for cancer. We …

IL-27 Gene Therapy Induces Stat3-Mediated Expansion of CD11b+Gr1+ Myeloid Cells and Promotes Accumulation of M1 Macrophages in the Tumor …

J Zhu, J Yu, A Hu, JQ Liu, X Pan, G Xin… - The Journal of …, 2023 - journals.aai.org
IL-27 is a pleiotropic cytokine that exhibits stimulatory/regulatory functions on multiple
lineages of immune cells and has a potential to be used as a therapeutic for cancer. We …

IL-27 Gene Therapy Induces Stat3-Mediated Expansion of CD11b+ Gr1+ Myeloid Cells and Promotes Accumulation of M1 Macrophages in the Tumor …

J Zhu, J Yu, A Hu, JQ Liu, X Pan… - Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
IL-27 is a pleiotropic cytokine that exhibits stimulatory/regulatory functions on multiple
lineages of immune cells and has a potential to be used as a therapeutic for cancer. We …

IL-27 Gene Therapy Induces Stat3-Mediated Expansion of CD11b+ Gr1+ Myeloid Cells and Promotes Accumulation of M1 Macrophages in the Tumor …

J Zhu, J Yu, A Hu, JQ Liu, X Pan… - Journal of …, 2023 - ohiostate.elsevierpure.com
IL-27 is a pleiotropic cytokine that exhibits stimulatory/regulatory functions on multiple
lineages of immune cells and has a potential to be used as a therapeutic for cancer. We …